Skip to Content
Merck
  • Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1.

Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1.

Molecular medicine reports (2017-03-30)
Chen Liu, Chaoyu Mu, Zeng Li, Liang Xu
ABSTRACT

Overexpression of peptidyl-prolyl cis/trans isomerase, NIMA interacting‑1 (Pin1) is a significant marker of the occurrence and development of tumors. In the present study, the imidazoline ketone herbicide imazamethabenz was investigated as a potential antitumor drug by inhibiting Pin1. Molecular docking and enzyme activity tests verified, for the first time, that the imidazoline ketone compound imazamethabenz effectively inhibited Pin1 in vitro. MTT assays, western blotting, wound healing assay and Matrigel invasion assays revealed that imazamethabenz induced apoptosis and inhibited migration and invasion of the breast cancer cell line MCF‑7, which overexpresses Pin1, by inhibiting the Pin1‑mediated signaling pathway involving vascular endothelial growth factor and matrix metalloproteinase 9. These findings indicated that imazamethabenz offers potential applications for the treatment of tumors as a Pin1 inhibitor.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Rabbit IgG (whole molecule)–Peroxidase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-Mouse IgG (whole molecule)–Peroxidase antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-MMP-9 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse, clone 26503, purified immunoglobulin, lyophilized powder
Sigma-Aldrich
Anti-β-Actin antibody, Mouse monoclonal, clone AC-15, purified from hybridoma cell culture